FBXW7 and leukemia: Meanwhile, miR-223-3p was found to target Fbxw7 (Fig 5B), a cell cycle regulator that promotes c-Myc and cyclin E degradation [61], suggesting that the well-documented miR-223/Fbxw7 axis [62, 63] is functionally active in HCC, in addition to modulating resistance to γ-secretase inhibitor treatment in leukemia [64] and resistance to cisplatin in gastric cancers [57].